Femasys stock.

Femasys: Other Events, Financial Statements And Exhibits. November 28, 2023 U.S. Securities and Exchange Commission. Item 8.01 Other Events On November 28, 2023, Femasys Inc. (the “Company”) announced the completion of enrollment in pivotal trial of its intratubal insemination product FemaSeed. A copy of the press release is being …Nasdaq 14,272.37 +1.04% Crude Oil 78.16 +2.99% US 10 Yr 100.69 +2,184.99% Euro 1.09 +0.31% Dow Jones 35,124.97 +0.51% Russell 2000 1,805.52 …WebAn Atlanta woman-founded, women's healthcare company plans to raise $40 million in an initial public stock offering. Suwanee-based Femasys Inc. says in plans filed May 14 with the Securities and ...Femasys Inc (FEMY) stock is trading at $1.10 as of 10:08 AM on Wednesday, Nov 15, an increase of $0.17, or 18.28% from the previous closing price of $0.93. The stock has traded between $1.05 and $1.25 so far today. Volume today is 2,748,419 compared to average volume of 3,456,068.ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office ...

Oct 11, 2023 · Femasys was previously notified by Nasdaq on June 1, 2023 that it was not in compliance with the minimum bid price rule (“the Rule”) because its common stock failed to meet the closing bid ...

See the company profile for Femasys Inc. (FEMY) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and their ...

Femasys’ FemaSeed ® Intratubal Insemination, an innovative infertility treatment designed to deliver sperm directly where conception occurs, is now FDA-cleared (and also approved in Canada). The Company has developed diagnostic products that are complementary for which it has achieved regulatory approvals to market in the U.S., Canada and ...Get the latest Femasys Inc. (FEMY) stock news and headlines to help you in your trading and investing decisions.WebYou may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.Overview. Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health.

The Zacks Consensus Estimate for Femasys’ sales in the third quarter of 2023 is pegged at $0.4 million. However, sales in the United States declined year over year in the second quarter of 2023 ...

Femasys Inc FEMY shares surged after the company received FDA 510 (k) clearance for FemaSeed, an infertility treatment designed to deliver sperm directly to where conception occurs in a woman's fallopian tube. Infertility has affected an increasing number of women – estimated at 10 million in the U.S., according to the Center for Disease Control.

Short interest for Femasys gives investors a sense of the degree to which investors are betting on the decline of Femasys's stock. Short interest data is updated every two weeks.Nov 29, 2023 · Femasys GAAP EPS of -$0.22 misses by $0.02, revenue of $0.32M misses by $0.05M SA News Thu, Aug. 10 Femsys stock jumps 21% after FDA green lights FemBloc testing Get the latest Femasys Inc (FEMY) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Nov. 30, 2023 5:40 PM ET Femasys Inc. (FEMY) By: Tiyashi Datta, SA News Editor. Femasys ( NASDAQ: FEMY) filed a prospectus related to the offer and resale by the selling stockholders of up to an ...146.71. +1.95%. 45.70M. View today's Femasys Inc stock price and latest FEMY news and analysis. Create real-time notifications to follow any changes in the live stock price.Web

Femasys share price went down by -34.75% last month. The next quarterly earnings date for Femasys is scheduled on November 17, 2023. Femasys's next ex-dividend date is November 17, 2023.In a concurrent private placement, Femasys has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 3,196,722 shares of common stock.A few examples include why shares of Tharimmune (NASDAQ: THAR) and Femasys (NASDAQ: FEMY) stock are up, as well as the biggest pre-market stock movers for today. All of that info is available at ...Femasys is a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead revolutionary late ...PR Newswire — Thinking about buying stock in Ardelyx, Rivian Automotive, Femasys, Lucid Group, or Outlook Therapeutics? News • Oct 11, 2023 Morningstar — Femasys Inc. Regains Compliance with Nasdaq Listing Requirements

HC Wainwright & Co. analyst Emily Bodnar maintained Femasys with a Buy rating and raised the price target from $5 to $13 on Friday. Femasys also announced last week that it has activated enrollment for its FemBloc trial to investigate a permanent birth control candidate. Shares of FEMY are moving higher on very heavy trading volume.

Jul 27, 2023 · Shares of biomedical firm Femasys soared on Thursday.; Management announced the issuance of a notice of allowance for its patent application. FEMY stock soared on IP protection of its first-of-its ... Aug 10, 2023 · Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update. August 10, 2023 08:00 ET ... Common stock, $.001 par, 200,000,000 authorized, ... Femasys was previously notified by Nasdaq on June 1, 2023 that it was not in compliance with the minimum bid price rule (“the Rule”) because its common stock failed to meet the closing bid ...Description. Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient ... - The 510(k) Clearance from the United States Food and Drug Administration (FDA) allows for the U.S. commercialization of FemaSeed ®, an intratubal artificial insemination option designed to augment the natural fertilization process - - FemaSeed ® is an innovative infertility treatment designed to deliver sperm directly to where conception …Femasys-stock Femasys Inc Registered Shs Stock , FEMY 0.95 -0.01 -1.53% After-market 07:34:36 PM EDT 11/17/2023 NAS Add to watchlist 0.96 +0.04 …WebFundamentals Market Capitalization, $K 14,544 Shares Outstanding, K 15,073 Annual Sales, $ 1,210 K Annual Income, $ -11,390 K 60-Month Beta -3.56 Price/Sales 11.50 …Web

Femasys Inc.is a biomedical company focused on transforming women's healthcare by developing novel solutions as well as providing significant clinical impact to address severely underserved areas. The company's lead product candidates offer FemBloc and FemaSeed. Femasys Inc. is based in ATLANTA. Stock split history for Femasys since 2021.

In a concurrent private placement, Femasys has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 3,196,722 shares of common stock. The offering is expected to close on or about April 20, 2023, subject to the satisfaction of customary closing conditions.

Femasys Inc () Stock Market info Recommendations: Buy or sell Femasys stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Femasys share forecasts, stock quote and buy / sell signals below.According to present data Femasys's FEMY shares and potentially its market environment have been in bearish …Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch - Topline results from FemaSeed® pivotal trial expected in 1H 2024 - - …WebNov 30, 2023 · ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office ... HC Wainwright & Co. analyst Emily Bodnar maintained Femasys with a Buy rating and raised the price target from $5 to $13 on Friday. Femasys also announced last week that it has activated enrollment for its FemBloc trial to investigate a permanent birth control candidate. Shares of FEMY are moving higher on very heavy trading volume.Oct 24, 2023 · Femasys is a commercial-stage company with four approved products — FemaSeed (intratubal Insemination), FemVue (contrast generating device), FemCath (selective delivery catheter) and FemCerv ... Femasys Inc. announced that it has entered into a Securities Purchase Agreement with new lead investor PharmaCyte Biotech, Inc. to issue 6% senior unsecured convertible notes for the gross proceeds...On average, Wall Street analysts predict. that Femasys's share price could reach $9.00 by Nov 14, 2024. The average Femasys stock price prediction forecasts a potential upside of 821.19% from the current FEMY share price of $0.98. Operating Status Active. Last Funding Type Post-IPO Debt. Legal Name Femasys Inc. Stock Symbol NASDAQ:FEMY. Company Type For Profit. Contact Email [email protected]. Phone Number 1 (770) 500-3910. Femasys is a biomedical company focused on transforming women’s healthcare worldwide by …LAS VEGAS, November 15, 2023--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) ("PharmaCyte" or the "Company") announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) ("Femasys"), a biomedical company focused on meeting significant unmet needs for women worldwide. Femasys offers a broad portfolio of in-office, accessible solutions ... Dec 31, 2022 · Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law. Contacts: Investors Chuck Padala LifeSci Advisors, LLC +1-917-741-7792 [email protected]. Femasys Inc. Investor Contact: [email protected]. Media Contact ... Femasys Inc (NASDAQ:FEMY) trade information. Femasys Inc (FEMY) registered a -2.33% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -2.33% in intraday trading to $0.93 this Friday, 12/01/23, hitting a weekly high. The stock’s 5-day price performance is -9.71%, and it has moved …Short interest for Femasys gives investors a sense of the degree to which investors are betting on the decline of Femasys's stock. Short interest data is updated every two weeks.

Femasys (NASDAQ:FEMY) filed a prospectus related to the offer and resale by the selling stockholders of up to an aggregate of 18.11M shares of common stock …WebNov 30, 2023 · According to 3 stock analysts, the average 12-month stock price forecast for Femasys stock is $9.00, which predicts an increase of 845.18%. The lowest target is $7.00 and the highest is $10. On average, analysts rate Femasys stock as a strong buy. FEMY Earnings Date and Information. Femasys has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, April 4th, 2024 based off prior year's report dates. Read More.A A. 0. On September 26, 2023, Lina Kaminski, an analyst at JonesTrading, expressed her positive outlook on Femasys (NASDAQ:FEMY) by maintaining a Buy rating and increasing the price target to $7. This indicates her belief that investing in Femasys is a wise decision and she anticipates the stock reaching $7 per share.Instagram:https://instagram. crypto portfolio appmarathon oil stock forecast2009d penny valueforex training app Femasys Inc () Stock Market info Recommendations: Buy or sell Femasys stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Femasys share forecasts, stock quote and buy / sell signals below.According to present data Femasys's FEMY shares and potentially its market environment have been in bearish …MarketWatch IBD DJIA 35336.10 0.15% S&P 500 4553.34 0.13% U.S. 10 Yr 3/32 Yield 4.434% Euro 1.0937 0.10% Subscribe Sign In Femasys Inc. FEMY (U.S.: Nasdaq) Overview News Femasys Inc. No... electric vehicle stockscompare brokers for online trading 0.13% QQQ 389.08 0.11% SPIKE – 3.39% BTC/USD 37034.02 0.9542% DIA 353.48 0.09% 187.02 0.81% TLT 91.10 1.45% Femasys Inc (NASDAQ:FEMY) $1.04 …Web webull or etrade The Zacks Consensus Estimate for Femasys’ sales in the third quarter of 2023 is pegged at $0.4 million. However, sales in the United States declined year over year in the second quarter of 2023 ...Dec 31, 2022 · Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law. Contacts: Investors Chuck Padala LifeSci Advisors, LLC +1-917-741-7792 [email protected]. Femasys Inc. Investor Contact: [email protected]. Media Contact ...